Trials / Completed
CompletedNCT00193271
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.
Detailed description
Upon determination of eligibility, patients will receive: Docetaxel + Estramustine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | |
| DRUG | Estramustine |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2005-09-19
- Last updated
- 2011-05-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00193271. Inclusion in this directory is not an endorsement.